RWE, Market Access, Pricing & Reimbursement Global Congress 2021 Europe

Days
Hours
Minutes
Seconds

8th - 9th November 2021 - 2 Day Conference
London, UK

Venue

London, UK

Address

TBC

Phone

TBC

RWE, Market Access, Pricing & Reimbursement

Global Congress 2021 Europe

At a global scale, pharmaceutical market is expected to grow in the years to come regardless of recent slowdown in key markets across the globe. The increase is exacerbated by the growing and ageing population in key markets. Aside from this, increasing access of Pharmaceuticals to poor and middle-class families due to increases in disposable income also driving the growth of the industry. Pharma companies focusing on Rare and speciality medicines is another aspect leading the growth. Innovations attracting investments even from non-pharma companies are also sustaining the growth in the pharmaceutical industry.

The pharmaceutical industry is one of the major players in the healthcare sector. Governments across Europe are struggling to balance the desire to provide timely access to innovative medicines with the need to contain healthcare spending due to the increasing pressure between the demands of the EU, national governments and regional authorities.

Read Full Introduction
Insights & Attendees
Scroll to Top

Dear Colleagues,

At a global scale, pharmaceutical market is expected to grow in the years to come regardless of recent slowdown in key markets across the globe. The increase is exacerbated by the growing and ageing population in key markets. Aside from this, increasing access of Pharmaceuticals to poor and middle-class families due to increases in disposable income also driving the growth of the industry. Pharma companies focusing on Rare and speciality medicines is another aspect leading the growth. Innovations attracting investments even from non-pharma companies are also sustaining the growth in the pharmaceutical industry.

The pharmaceutical industry is one of the major players in the healthcare sector. Governments across Europe are struggling to balance the desire to provide timely access to innovative medicines with the need to contain healthcare spending due to the increasing pressure between the demands of the EU, national governments and regional authorities.

As healthcare budgets are continuously rising in Europe, governments implement a wide variety of policies to control them with the help of different public regulatory bodies that are involved in pharmaceutical coverage decisions across Europe. International collaboration among HTA and regulatory bodies can promote knowledge exchange, efficiency of information production and prepare developing systems for new challenges.

The upcoming 2020 Market Access, Pricing and Reimbursement Global Congress Europe will present a dynamic approach to key trends and insights on market access, health technology assessment, real world data, patient access, pricing and reimbursement on the current European landscape.

This year, we are putting together an agenda that addresses “Factors driving the success of Market Access Strategies”. We are gathering together high calibre expert speakers to participate and share their knowledge and expertise through Keynote Presentations and Panel discussions, addressing all aspect of the industry.

We look forward to welcoming you at the MAPR 2020 congress!

Sincerely yours,

Jocelyn Raguindin
Jocelyn Raguindin

Jocelyn is Conference Director at Paradigm Global Events (PGE). She has over 15+ years experience in organizing pharma-industry conferences and has been at the helm of every PGE conference since 2013. Jocelyn is based in London, UK.

Why you should attend:

  • Take part on important interactive discussions on current trends and best practices
  • Learn from your peers about pricing and reimbursement systems in their market
  • Know how to develop a Market Access Plan and how to communicate value to stakeholders
  • Learn the Market Access environment in Europe’s major markets
  • Hear an overview of the market access system in place in large pharma markets
  • Real word evidence and HEOR
  • Growth of biosimilars and importance of RWE for orphan drugs and rare diseases
  • The role of emerging markets
  • Challenges and opportunities in pricing, reimbursement and patient access
  • Risk sharing agreements, benefits and challenges
  • Global and European MA trends, collaboration and spill overs
  • Learn how to implement a successful market access strategy

You Will Meet:

Network with members of boards, VP’s, Directors, Heads/Chiefs and Senior Managers of leading biopharmaceutical and biotech companies, government, CRO and solution providers involved in:

  • Market Access
  • Reimbursement
  • Patient Outcomes
  • Drug Pricing
  • Health Economics and Outcomes Research
  • Payer Relations/ Evidence
  • Regulatory Affairs
  • Public / Government Affairs
  • Payers, HTA Officials and Physicians
  • Business Development
  • Marketing
  • Commercial Executives
  • Product Launch
  • Real World Evidence
  • Commercialisation
  • Value Strategy
  • Product Strategy
  • Forecaster
  • Finance Officer